Daniel Drucker shares $3 million US prize with colleagues A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes and obesity medications including Ozempic, Wegovy and Mounjaro that have changed the lives of millions of people around the world
While other polyphenols in APE, such as catechins, chalcones, and phenol carboxylic acids, demonstrated minimal impact on lipase activity
In combination, BPC-157 and TB-500 provide a research framework for examining how peptide signaling influences cellular migration, vascular communication, and structural tissue organization in skeletal muscle models
Researchers at USC Schaeffer recently proposed a value-based price framework for anti-obesity medications that attempts to account for lifetime outcomes across multiple domains
RESULTS Solidifying evidence for the existence of gene X The existence of a missing GSC self-renewal regulator, gene X, was proposed because of striking differences in GSC defects upon removal of either the GLP-1/Notch receptor or its target genes ( lst-1 and sygl-1 ) on the one hand and removal of FBF-1 and FBF-2 on the other (Figure 1B) (AUSTIN AND KIMBLE 1987
